NanoTechnology PASADENA, Calif., May 27, 2010 (BUSINESS WIRE) -- Arrowhead Research Corporation /quotes/comstock/15*!arwr/quotes/nls/arwr (ARWR 1.33, +0.04, +2.95%) today announced that two articles of interest to Arrowhead stockholders appeared in the Houston Chronicle this week. An article published on May 24, entitled "Minute invaders that aid the body", reports on the revolutionary potential of gene silencing and the pioneering role of the siRNA delivery system developed by Arrowhead majority-owned subsidiary, Calando Pharmaceuticals and Caltech engineering professor, Dr. Mark Davis. The article described preliminary data from Calando's Phase I clinical trial, recently published in the journal Nature, that demonstrated effective siRNA delivery to tumor cells and gene silencing via RNAi for the first time in humans. Dr. Davis discussed the results, and Dr. Mauro Ferrari, Chairman of NanoMedicine and Biomedical Engineering at the University of Texas Medical School, is quoted in the article about the work and the power of RNA interference: "These are very sophisticated ways of sending biological messages to the body. It will change medicine completely."
Here is another example of significant traction in the commercialization of nanomedicine.
NanoTumor Center Overview